Published in Science on March 26, 2010
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
Wnt signaling in cancer. Cold Spring Harb Perspect Biol (2012) 2.75
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
RNAi screens in mice identify physiological regulators of oncogenic growth. Nature (2013) 2.46
WNT signaling underlies the pathogenesis of neuropathic pain in rodents. J Clin Invest (2013) 2.42
The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol (2011) 1.95
Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet (2014) 1.94
Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell (2016) 1.91
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell (2013) 1.89
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood (2014) 1.89
The canonical Wnt pathway shapes niches supportive of hematopoietic stem/progenitor cells. Blood (2011) 1.89
BET inhibitor resistance emerges from leukaemia stem cells. Nature (2015) 1.88
Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer (2010) 1.77
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature (2015) 1.75
MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood (2011) 1.74
Decoupling of tumor-initiating activity from stable immunophenotype in HoxA9-Meis1-driven AML. Cell Stem Cell (2012) 1.71
Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget (2010) 1.71
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia (2012) 1.64
Drugging Wnt signalling in cancer. EMBO J (2012) 1.63
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med (2014) 1.62
Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways. Nat Med (2012) 1.58
Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells. Blood (2015) 1.50
Understanding the cancer stem cell. Br J Cancer (2010) 1.42
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell (2013) 1.42
Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget (2010) 1.42
Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance. J Exp Med (2015) 1.41
Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia (2011) 1.37
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood (2012) 1.36
Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood (2011) 1.32
Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo. Oncogene (2011) 1.29
Zebrafish as tools for drug discovery. Nat Rev Drug Discov (2015) 1.28
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell (2014) 1.28
mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest (2012) 1.27
Recent advances in acute myeloid leukemia stem cell biology. Haematologica (2012) 1.25
Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell (2011) 1.25
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood (2012) 1.25
Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep (2012) 1.24
Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells. Cell Stem Cell (2012) 1.24
The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. J Clin Invest (2012) 1.24
Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. Cell Stem Cell (2014) 1.23
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia (2013) 1.22
Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood (2012) 1.21
Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell (2015) 1.20
Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia. Oncogene (2013) 1.20
Advances in understanding the leukaemia microenvironment. Br J Haematol (2014) 1.19
Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol (2011) 1.17
Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med (2013) 1.15
Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev (2014) 1.15
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol (2012) 1.15
β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids. Oncogene (2014) 1.14
Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol (2013) 1.14
Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer. Oncotarget (2012) 1.12
Cadmium induces carcinogenesis in BEAS-2B cells through ROS-dependent activation of PI3K/AKT/GSK-3β/β-catenin signaling. Toxicol Appl Pharmacol (2012) 1.11
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity. J Clin Invest (2014) 1.11
Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res (2012) 1.11
miR-99a/100~125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling. Genes Dev (2014) 1.11
Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ (2014) 1.10
The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol (2013) 1.09
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors. Cancer Res (2012) 1.06
Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood (2014) 1.04
Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol (2013) 1.04
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy. Cell Stem Cell (2014) 1.04
Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. J Clin Invest (2015) 1.03
Inhibition of androgen receptor and β-catenin activity in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.01
The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ (2013) 1.01
CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression. J Clin Invest (2012) 0.99
Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood (2015) 0.97
Characterizing heterogeneity in leukemic cells using single-cell gene expression analysis. Genome Biol (2014) 0.97
Drugging the cancer stem cell compartment: lessons learned from the hedgehog and Wnt signal transduction pathways. Annu Rev Pharmacol Toxicol (2011) 0.97
Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. Cell Stem Cell (2015) 0.96
Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. J Exp Med (2013) 0.96
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia (2010) 0.95
Wnt signaling in cancer. Oncogene (2016) 0.95
Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nat Genet (2015) 0.94
Wnt/β-catenin Signaling in Normal and Cancer Stem Cells. Cancers (Basel) (2011) 0.94
A role for GPx3 in activity of normal and leukemia stem cells. J Exp Med (2012) 0.94
The Risa R/Bioconductor package: integrative data analysis from experimental metadata and back again. BMC Bioinformatics (2014) 0.93
β-Arrestin2 mediates the initiation and progression of myeloid leukemia. Proc Natl Acad Sci U S A (2012) 0.93
Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways. J Cell Sci (2011) 0.92
Preferential eradication of acute myelogenous leukemia stem cells by fenretinide. Proc Natl Acad Sci U S A (2013) 0.92
Role of Microenvironment in Resistance to Therapy in AML. Curr Hematol Malig Rep (2015) 0.92
Leukemia cells induce changes in human bone marrow stromal cells. J Transl Med (2013) 0.92
Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther (2014) 0.92
β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS Genet (2013) 0.91
Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism. FASEB J (2013) 0.91
Active enhancers are delineated de novo during hematopoiesis, with limited lineage fidelity among specified primary blood cells. Genes Dev (2014) 0.91
Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia. Br J Haematol (2014) 0.90
miR-590-5p, miR-219-5p, miR-15b and miR-628-5p are commonly regulated by IL-3, GM-CSF and G-CSF in acute myeloid leukemia. Leuk Res (2011) 0.90
Evidence for tankyrases as antineoplastic targets in lung cancer. BMC Cancer (2013) 0.90
Biology of colorectal cancer. Ecancermedicalscience (2015) 0.90
Cancer stem cells: a stride towards cancer cure? J Cell Physiol (2010) 0.90
AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway. Blood (2013) 0.90
Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine. Curr Med Chem (2015) 0.89
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia (2014) 0.88
Targeting the canonical Wnt/β-catenin pathway in hematological malignancies. Cancer Sci (2015) 0.88
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature (2003) 12.81
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med (2004) 11.29
Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development (2001) 9.00
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Stem cell concepts renew cancer research. Blood (2008) 6.74
Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell (2006) 6.34
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science (2005) 5.68
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J (1998) 5.21
Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev (2003) 4.71
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell (2007) 4.21
Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev (1995) 3.81
Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med (2004) 3.16
Long-term, multilineage hematopoiesis occurs in the combined absence of beta-catenin and gamma-catenin. Blood (2007) 2.78
Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc Natl Acad Sci U S A (2009) 2.76
Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell (2009) 2.00
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther (2008) 1.83
Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia (2006) 1.58
Hox genes: from leukemia to hematopoietic stem cell expansion. Ann N Y Acad Sci (2005) 1.37
The role of cyclooxygenase-2 and prostaglandins in colon cancer. Prostaglandins Other Lipid Mediat (2006) 1.29
Indomethacin decreases arachidonic acid uptake in HCA-7 human colon cancer cells. J Pharmacol Sci (2008) 0.91
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Hematopoiesis: an evolving paradigm for stem cell biology. Cell (2008) 11.95
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
The zebrafish reference genome sequence and its relationship to the human genome. Nature (2013) 8.52
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature (2007) 7.55
Transplantation and in vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nat Immunol (2003) 5.73
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab (2005) 5.32
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell (2008) 5.09
Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A (2010) 4.99
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell (2009) 4.69
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proc Natl Acad Sci U S A (2005) 4.15
p53 regulates maternal reproduction through LIF. Nature (2007) 4.12
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol (2005) 3.68
Genetic analysis of cavefish reveals molecular convergence in the evolution of albinism. Nat Genet (2005) 3.66
Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci (2002) 3.64
Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev (2007) 3.45
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol (2008) 3.43
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature (2011) 3.37
β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell (2012) 3.33
Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev (2005) 3.27
Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med (2003) 3.21
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet (2011) 3.18
Myc-induced T cell leukemia in transgenic zebrafish. Science (2003) 3.15
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
The use of zebrafish to understand immunity. Immunity (2004) 3.09
Mitoferrin is essential for erythroid iron assimilation. Nature (2006) 2.99
SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization. Mol Cell (2002) 2.93
Central administration of oleic acid inhibits glucose production and food intake. Diabetes (2002) 2.91
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
Hematopoietic stem cell development is dependent on blood flow. Cell (2009) 2.77
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev (2006) 2.66
Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood (2005) 2.65
Teratoma formation assays with human embryonic stem cells: a rationale for one type of human-animal chimera. Cell Stem Cell (2007) 2.56
The 'definitive' (and 'primitive') guide to zebrafish hematopoiesis. Oncogene (2004) 2.54
Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell (2011) 2.53
Effects of lethal irradiation in zebrafish and rescue by hematopoietic cell transplantation. Blood (2004) 2.46
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell (2010) 2.33
Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesis. Nature (2005) 2.25
DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature (2011) 2.23
A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. Proc Natl Acad Sci U S A (2005) 2.19
BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox pathway. Cell Stem Cell (2008) 2.17
cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. Nature (2003) 2.16
Mutant-specific gene programs in the zebrafish. Blood (2005) 2.15
Zebrafish as a cancer model system. Cancer Cell (2002) 2.12
Loss of gata1 but not gata2 converts erythropoiesis to myelopoiesis in zebrafish embryos. Dev Cell (2005) 2.12
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood (2007) 2.12
Ubiquitous transgene expression and Cre-based recombination driven by the ubiquitin promoter in zebrafish. Development (2011) 2.11
An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr Biol (2004) 2.10
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell (2011) 2.04
Use of the zebrafish system to study primitive and definitive hematopoiesis. Annu Rev Genet (2005) 2.02
Hooked! Modeling human disease in zebrafish. J Clin Invest (2012) 2.00
The transcriptional landscape of hematopoietic stem cell ontogeny. Cell Stem Cell (2012) 1.96
The zebrafish as a model organism to study development of the immune system. Adv Immunol (2003) 1.96
Regulation of the lmo2 promoter during hematopoietic and vascular development in zebrafish. Dev Biol (2005) 1.93
Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell (2010) 1.92
Hematopoiesis and stem cells: plasticity versus developmental heterogeneity. Nat Immunol (2002) 1.90
APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. Dev Biol (2008) 1.90
Ultrasound biomicroscopy permits in vivo characterization of zebrafish liver tumors. Nat Methods (2007) 1.90
Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc Natl Acad Sci U S A (2011) 1.87
Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat Chem Biol (2005) 1.87
T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell (2010) 1.85
In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proc Natl Acad Sci U S A (2004) 1.85
SUMO-1 protease-1 regulates gene transcription through PML. Mol Cell (2002) 1.80
Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proc Natl Acad Sci U S A (2009) 1.79
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
The clinical potential of stem cells. Curr Opin Cell Biol (2004) 1.73
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood (2013) 1.72